Summary In 2018, the US National Institute on Aging and the Alzheimer's Association
proposed a purely biological definition of Alzheimer's disease that relies on biomarkers …

In this Seminar, we highlight the main developments in the field of Alzheimer's disease. The
most recent data indicate that, by 2050, the prevalence of dementia will double in Europe …

Abstract Background Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially
targets soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils, and …

Abstract Background Lecanemab, a humanized IgG1 monoclonal antibody that targets
soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid …

Alzheimer's disease is a progressive, irreversible neurodegenerative disease impacting
cognition, function, and behavior. Alzheimer's disease progresses along a continuum from …

Cognitive dysfunction is increasingly recognized as an important comorbidity of diabetes
mellitus. Different stages of diabetes-associated cognitive dysfunction exist, each with …

Abstract Background Prodromal Alzheimer's disease offers an opportunity to test the effect of
drugs that modify the deposition of amyloid in the brain before the onset of dementia …

Abstract In 2011, the National Institute on Aging and Alzheimer's Association created
separate diagnostic recommendations for the preclinical, mild cognitive impairment, and …

The reconceptualization of Alzheimer's disease (AD) as a clinical and biological construct
has facilitated the development of biomarker-guided, pathway-based targeted therapies …

The development of microneedles (MNs) assisted drug delivery technologies have been
highly active for more than two decades. The minimally invasive and self-administered MN …